SCHEMBL17010756

SCHEMBL17010756

O=C(Oc1ccc(Cl)cc1Cl)c1ccccc1Oc1ccc(Cl)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.56
MAPT P10636 4/20 0.53
PLA2G1B P04054 1/20 0.53
ATG4B Q9Y4P1 1/20 0.53
NPSR1 Q6W5P4 2/20 0.52
SLC6A2 P23975 3/20 0.50
SLC6A3 Q01959 3/20 0.50
HPGD P15428 2/20 0.50
TTR P02766 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NR1I2 O75469 1/20 0.50
LMNA P02545 1/20 0.50
PGR P06401 1/20 0.50
HSP90AA1 P07900 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
HSPA5 P11021 1/20 0.50
CBR1 P16152 1/20 0.50
TBXA2R P21731 1/20 0.50
AGTR1 P30556 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9389239 0.89 KMT2A (0.56) CHRM1MAPTPLA2G1BATG4BHPGD
SCHEMBL641133 0.84 HPGD (0.62) CHRM1MAPTPLA2G1BATG4BSLC6A2
SCHEMBL4150117 0.83 CHRM1 (0.57) CHRM1MAPTPLA2G1BATG4BSLC6A2
SCHEMBL8210159 0.83 ESR1 (0.58) MAPTSLC6A2SLC6A3HPGDTTR
SCHEMBL18642084 0.83 CHRM1 (0.54) CHRM1MAPTPLA2G1BATG4BNPSR1
SCHEMBL7071994 0.78 MRGPRX4 (0.56) CHRM1MAPTPLA2G1BATG4BSLC6A2
SCHEMBL8207859 0.78 MRGPRX4 (0.55) CHRM1MAPTPLA2G1BATG4BHPGD
SCHEMBL1037978 0.77 CHRM1 (0.57) CHRM1MAPTPLA2G1BATG4BSLC6A2
SCHEMBL11484178 0.75 ALDH1A1 (0.58) CHRM1MAPTPLA2G1BATG4BHPGD
SCHEMBL10602875 0.75 PTK2B (0.70) MAPTNPSR1HPGDKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3104835-B1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION RECKITT BENCKISER LLC (US) 2019-02-13 EP disclosed
US-9877484-B2 Pulvurent effervescent topical treatment composition RECKITT BENCKISER LLC (US) 2018-01-30 US disclosed
US-20170006874-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION RECKITT BENCKISER LLC (US) 2017-01-12 US disclosed
EP-3104835-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION Reckitt Benckiser LLC (US) 2016-12-21 EP disclosed
WO-2015121659-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION RECKITT BENCKISER LLC (US) 2015-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170006874-A1 PULVURENT EFFERVESCENT TOPICAL TREATMENT COMPOSITION SOST, FPR2, SHH CHRM1 403/4885MAPT 1882/4885PLA2G1B 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.